Perflutren Lipid Microsphere Intravenous Suspension
Stage II Pancreatic Cancer AJCC v8
Flemming ForsbergPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
36 Active assets in the Stage II Pancreatic Cancer AJCC v8 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olaparib MOMA Therapeutics | Phase 2 | BB |
Gdc-0449 OHSU Knight Cancer Institute | Phase 2 | BB |
Palbociclib National Cancer Institute (NCI) | Phase 2 | BB |
Trastuzumab Emtansine OHSU Knight Cancer Institute | Phase 2 | B |
Cobimetinib N.N. Petrov National Medical Research Center of Oncology | Phase 2 | B |
View all 50 →
Same molecule, other indications
Perflutren Lipid Microsphere Intravenous Suspension is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →